Search

everythinglearnresearchcommunity

for

Search:↓

Upadacitinib improved multiple immune-related conditions in one patient.

A 13-year-old girl with various symptoms was successfully treated with an antibiotic called co-trimoxazole.

Ruxolitinib may effectively treat APS-1 by reducing harmful immune responses.

Children with different rheumatologic diseases have specific skin symptoms that can help with diagnosis.

Non-invasive methods show promise for diagnosing skin diseases like psoriasis and lupus but need more research for regular use.

Depression and skin autoimmune diseases are linked, needing combined care for better treatment.

Psoriasis may be chronic because it lacks certain immune system controls that prevent overreaction.

Infliximab improved skin and bowel symptoms in Crohn's disease but caused side effects and the disease returned after stopping treatment.

The document concludes that corticosteroids effectively treat vasculitis allergica in over 90% of cases, with long-term kidney issues being the main adverse outcome.

People with primary immunodeficiencies often have frequent, severe, or unusual infections and may need special tests and management strategies.

More effective treatments are needed for alopecia areata, hidradenitis suppurativa, and vitiligo.

T cells and inflammation are crucial in atherosclerosis, with anti-inflammatory treatments showing promise.

TNF-inhibitor induced alopecia can be treated effectively with different therapies.

Recombinant cytokine therapy can cause skin reactions ranging from mild to severe.

Anti-TNF therapy can cause hair loss and skin issues.

Volatile organic compounds can cause inflammation and increase the risk of autoimmune diseases.

Infliximab can cause SAPHO syndrome, which may improve with Spesolimab and methotrexate.

Follicular dystrophy in immunocompromised patients may be linked to medication or viral factors and can improve with treatment changes.

Chronic skin diseases and metabolic syndrome are linked by shared inflammation pathways.

Improving diet and lifestyle can help manage skin conditions linked to insulin resistance and inflammation.

Biologics and small molecules can effectively treat inflammatory nail disorders, but personalized treatment plans are important.

The document concludes that DAB389-IL2 is promising for treating refractory cutaneous T-cell lymphoma, but more research is needed on its effectiveness and side effect management.

Blocking EGFR can cause skin inflammation by disrupting IL-1 signaling.

IL-2 treatment causes skin eruptions and other reversible side effects, and may play a role in psoriasis.

New therapies for rare skin diseases show promise but need more research.

Some IBD patients on anti-TNFs developed severe skin issues, but ustekinumab helped.

Aging and chronic inflammation weaken the immune system, increasing cancer and infection risks.

The nail immune system is similar to hair but different from skin, with fewer immune markers.

Tocilizumab therapy may cause skin and hair conditions like halo naevi, vitiligo, and alopecia areata.